<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379353</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0980</org_study_id>
    <nct_id>NCT00379353</nct_id>
  </id_info>
  <brief_title>The Effects of Thalidomide on Symptom Clusters</brief_title>
  <official_title>The Effects of Thalidomide on Symptom Clusters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if thalidomide can improve symptoms such
      as pain, fatigue,anxiety, poor appetite, depression, and sleep problems in patients with
      advanced cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thalidomide is designed to change the immune system. It may also interfere with the
      development of tiny blood vessels that help support tumor growth.

      Before you can start treatment on this study, you will have &quot;screening tests.&quot; These tests
      will help the doctor decide if you are eligible to take part in this study. You will be asked
      about your cancer diagnosis, the drugs you are taking, and the symptoms you are having (for
      example, pain, fatigue, anxiety, depression, poor appetite, and sleep problems). Blood (about
      2 tablespoons) will be drawn to measure protein levels in your blood.

      Women who are able to have children must have a negative blood (about 1 tablespoon) pregnancy
      test 24 hours before beginning to receive thalidomide.

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in toss of a coin) to one of 2 groups. You will have an equal chance of being placed in
      either of the 2 groups. You, the medical staff, and researchers will not know which group you
      have been assigned to.

      Participants in Group 1, who are not on chemotherapy, will take 2 thalidomide capsules, by
      mouth, once a day for 14 days. Participants in Group 1, who are on chemotherapy, will take 1
      thalidomide capsule, by mouth, once a day for 7 days, and then 2 thalidomide capsules, by
      mouth, once a day for 7 days.

      Participants in Group 2, who are not on chemotherapy, will take 2 placebo capsules, by mouth,
      once a day for 7 days. Participants in Group 2, who are on chemotherapy, will take 1 placebo
      capsule, by mouth, once a day for 7 days, and then 2 placebo capsules, by mouth, once a day
      for 7 days. A placebo is a substance that looks like the study drug but has no active
      ingredients.

      You will complete 7 questionnaires, which will take about 30-60 minutes to complete. You will
      also have blood drawn (about 2 tablespoons) to measure protein levels in your blood. You will
      also have your body weight measured and be asked about your normal food intake. Your body
      composition will be measured using measurements that include body weight and height, skin
      fold thickness using Lange calipers, and bioelectrical impedance using the Tanita body
      composition monitoring scale. This is a non-invasive method to measure total body water,
      total body fat, and total body lean mass. The Tanita scale is similar to a typical weight
      scale, although unlike a weight scale, the Tanita scale measures body composition.
      Researchers will measure how much energy your body uses while at rest.

      Every week, women who are able to have children must have a negative blood (about 1
      tablespoon) pregnancy test.

      On Day 8 [± 3 days], you will complete 3 questionnaires. The 3 questionnaires include
      evaluation of your symptoms, fatigue level, and overall sense of well-being and should take
      about 30 minutes to complete.

      On Day 15 [± 3 days] you will have a study visit. You will be asked questions about any side
      effects you may have experienced. You will be asked about any symptoms of pain, fatigue,
      nausea, depression, poor appetite, and/or sleep problems. You will be asked to complete 7
      questionnaires which will take about 30-60 minutes to complete. You will also have your body
      weight measured and be asked about your normal food intake. Your body composition will be
      measured and researchers will measure how much energy your body uses while at rest. Blood
      (about 2 tablespoons) will be drawn to measure protein levels in your blood. All patients
      will be given the option to receive thalidomide until Day 30 [± 3 days].

      If you decide not to take thalidomide on Days 15-30, you will be considered off-study. If you
      decide to take thalidomide on Days 15-30, you will remain on study until Day 30. On Day 30 [±
      3 days], you will have end-of-study tests.

      On Day 30 [± 3 days], you will have an end-of-study visit. You will be asked questions about
      any side effects you may have experienced. You will be asked about any symptoms of pain,
      fatigue, anxiety, depression, poor appetite, and/or sleep problems.

      Blood (about 2 tablespoons) will be drawn to measure protein levels in your blood. You will
      be asked to complete 7 questionnaires which will take about 30-60 minutes to complete. You
      will also have your body weight measured and be asked about your normal food intake. Your
      body composition will be measured and researchers will measure how much energy your body uses
      while at rest.

      If you develop intolerable side effects, you will be taken off study. Otherwise, you will be
      considered off-study on either Day 15 [± 3 days] or Day 30 [± 3 days]. Blood (about 1
      tablespoon) will be drawn 2 weeks after thalidomide has been stopped to check for additional
      side effects.

      You and your doctor will have the option to continue your taking thalidomide off-study. You
      will participate in the S.T.E.P.S.® (System for Thalidomide Education and Prescribing Safety)
      program. This will include an additional consent, education about preventing pregnancy while
      taking thalidomide, and completing surveys about following the rules of this program.

      This is an investigational study. Thalidomide is FDA-approved and commercially available. Its
      use in this study, for this purpose, is investigational. Up to 62 patients will take part in
      this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Symptoms as Measured by Edmonton Symptom Assessment Scale (ESAS)</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>ESAS assessment of appetite (symptom) where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity. Evaluated at baseline [± 3 days], 2 weeks[± 3 days] and 4 weeks [± 3 days]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Anorexia/Cachexia Therapy (FAACT)</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>12-item symptom-specific subscale of the FACT-G designed to measure participants' additional concerns about their anorexia/cachexia during the previous 7 days. Participant rates concerns from 0 to 4 (0= not at all, 4= very much), combined are the 12 items subscales for a total of 0 to 48 where the higher number would represent greater concern.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>The FACIT-F consists of 27 general quality of life questions divided into 4 domains (physical, social, emotional and functional), plus a 13-item fatigue subscore. The participant rates the intensity of fatigue and its related symptoms on a scale of 0-4 (0= not at all, 4= very much) where the 13-item fatigue subscore totals are combined for a total of 0 to 52, with the higher number representing greater fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS) HADS-A (Anxiety)</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21). The higher the score The higher the score, the more likely the patient is showing signs of anxiety and as a result may benefit from a counseling/supportive session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS) HADS-D (Depression)</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21). The higher the score, the more likely the patient is showing signs of depression and as a result may benefit from a counseling/supportive session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>PSQI measures the quality and patterns of sleep. It differentiates poor from good sleep by measuring subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. A participant indicates how frequently each item was experienced on a scale from 0 to 3. The 7 component scores are then summed to obtain a global sleep score that can range from 0 to 21. A score of &gt;/= 5 indicates poor sleepers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Composition as Measured by Body Mass Index (BMI)</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>BMI, commonly used to measure overweight and obesity, is a measure of body fat based on a person's weight and height.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Cytokines and Receptors</measure>
    <time_frame>Baseline to Day 15</time_frame>
    <description>Cytokines Levels of IL-1β and its receptor IL RA, IL-6 its receptor IL-6R, and TNF-α and its receptors (i.e. tumor necrosis factor receptor (TNFR)) of TNFR1, TNFR2, IL-10, IL-8(serum) measured at baseline, Days 15 and 29. Multiplex bead Immunoassay used to measure serum/plasma levels of IL-1, IL-6, TNF-α, IL-10, IL-8 and their receptors where assay sensitivity for the cytokines was 3-6 pg/mL. Serum IL-10, IL-1β, IL-1RA, IL-6R, sTNF-RI, sTNF-R2 were also analyzed using an enzyme-linked immunosorbent assay device. Lowering cytokine levels can decrease fatigue, increase appetite and decrease anxiety and depression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Advanced Cancers</condition>
  <arm_group>
    <arm_group_label>Group 1: Thalidomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg capsules orally, once a day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo capsules orally, once a day for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>100 mg capsules orally, once a day for 14 days.</description>
    <arm_group_label>Group 1: Thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two placebo capsules orally, once a day for 14 days.</description>
    <arm_group_label>Group 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have weight loss of &gt; 5% within the last 6 months

          2. Present with anorexia, fatigue and one of the following: anxiety, depression or sleep
             disturbances, during the preceding 24 hours, with an average intensity of each symptom
             &gt;/= 3 on a scale of 0 to 10, in which 0=no symptom, and 10= the worst possible
             symptom.

          3. Describe the symptoms as being present every day for a minimum of 2 weeks.

          4. Have no clinical evidence of cognitive failure

          5. Must be 18 years or older.

          6. Expect to live at least &gt;/= 4 weeks

          7. Must have negative serum pregnancy test within 24 hours of study enrollment in women
             of childbearing potential. FDA criteria for the status of not of childbearing
             potential, hysterectomy, or menopausal for 24 consecutive months.

          8. Understand and sign written informed consent.

          9. Have no concurrent steroids with the exception of steroids used concurrently with
             chemotherapy as part of a regimen or to reduce nausea.

         10. Willing and able to comply with S.T.E.P.S.[System for Thalidomide Education and
             Prescribing Safety]

         11. Patient's Absolute neutrophil count (ANC) at time of study enrollment is &gt;/= 750 mm
             (to be drawn within 14 days prior to registration)

         12. May be on chemotherapy if at a stable dose. Targeted therapies or hormone therapies
             are permitted once patient has completed two weeks of treatment.

        Exclusion Criteria:

          1. Have major contraindication to thalidomide, i.e. hypersensitivity.

          2. Present with National Cancer Institute (NCI) Common Toxicity Criteria Grade 3 or more
             peripheral neuropathy.

          3. Are not able to complete the baseline assessment forms.

          4. Are pregnant or lactating.

          5. Patients with clinical history of seizures

          6. Patients with an ANC of &lt;/= 750 at time of study enrollment will be excluded (to be
             drawn within 14 days prior to registration).

          7. Patients with a history of Acquired Immune Deficiency Syndrome (AIDS), systemic lupus
             erythematous, or renal failure as defined by a serum creatinine of &gt; 2.0 mg/dl at
             baseline will be excluded (to be drawn within 29 days prior to registration).

          8. Patients on Revlimid (lenalidomide).

          9. Patients on investigational chemotherapy/agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Bruera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2006</study_first_submitted>
  <study_first_submitted_qc>September 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2006</study_first_posted>
  <results_first_submitted>July 3, 2012</results_first_submitted>
  <results_first_submitted_qc>November 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2013</results_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancers</keyword>
  <keyword>Anorexia</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 10/18/2006 through 10/27/2008. All participants recruited from UTMD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>The trial is now closed to new participant entry due to low accrual. Of the 31 participants recruited, 4 were not eligible for evaluation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Thalidomide</title>
          <description>100 mg capsules orally, once a day for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Placebo</title>
          <description>Two placebo capsules orally, once a day for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Hospitalization</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Cardiac Tamponade</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Conflicting drug treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Thalidomide</title>
          <description>100 mg capsules orally, once a day for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Placebo</title>
          <description>Two placebo capsules orally, once a day for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="24" upper_limit="81"/>
                    <measurement group_id="B2" value="65" lower_limit="49" upper_limit="81"/>
                    <measurement group_id="B3" value="60" lower_limit="24" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Anorexia/Cachexia Therapy (FAACT)</title>
        <description>12-item symptom-specific subscale of the FACT-G designed to measure participants' additional concerns about their anorexia/cachexia during the previous 7 days. Participant rates concerns from 0 to 4 (0= not at all, 4= very much), combined are the 12 items subscales for a total of 0 to 48 where the higher number would represent greater concern.</description>
        <time_frame>Baseline to Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Thalidomide</title>
            <description>100 mg capsules orally, once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Placebo</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Anorexia/Cachexia Therapy (FAACT)</title>
          <description>12-item symptom-specific subscale of the FACT-G designed to measure participants' additional concerns about their anorexia/cachexia during the previous 7 days. Participant rates concerns from 0 to 4 (0= not at all, 4= very much), combined are the 12 items subscales for a total of 0 to 48 where the higher number would represent greater concern.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="9" upper_limit="36"/>
                    <measurement group_id="O2" value="22.5" lower_limit="19" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="13" upper_limit="38"/>
                    <measurement group_id="O2" value="28" lower_limit="21" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="19" upper_limit="38"/>
                    <measurement group_id="O2" value="27" lower_limit="22" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)</title>
        <description>The FACIT-F consists of 27 general quality of life questions divided into 4 domains (physical, social, emotional and functional), plus a 13-item fatigue subscore. The participant rates the intensity of fatigue and its related symptoms on a scale of 0-4 (0= not at all, 4= very much) where the 13-item fatigue subscore totals are combined for a total of 0 to 52, with the higher number representing greater fatigue.</description>
        <time_frame>Baseline to Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Thalidomide</title>
            <description>100 mg capsules orally, once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Placebo</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)</title>
          <description>The FACIT-F consists of 27 general quality of life questions divided into 4 domains (physical, social, emotional and functional), plus a 13-item fatigue subscore. The participant rates the intensity of fatigue and its related symptoms on a scale of 0-4 (0= not at all, 4= very much) where the 13-item fatigue subscore totals are combined for a total of 0 to 52, with the higher number representing greater fatigue.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="7" upper_limit="35"/>
                    <measurement group_id="O2" value="20" lower_limit="15.5" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="4" upper_limit="39"/>
                    <measurement group_id="O2" value="24" lower_limit="17" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="9" upper_limit="34"/>
                    <measurement group_id="O2" value="24" lower_limit="18" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Anxiety and Depression Scale (HADS) HADS-A (Anxiety)</title>
        <description>The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0–3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0–21). The higher the score The higher the score, the more likely the patient is showing signs of anxiety and as a result may benefit from a counseling/supportive session.</description>
        <time_frame>Baseline to Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Thalidomide</title>
            <description>100 mg capsules orally, once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Placebo</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Anxiety and Depression Scale (HADS) HADS-A (Anxiety)</title>
          <description>The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0–3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0–21). The higher the score The higher the score, the more likely the patient is showing signs of anxiety and as a result may benefit from a counseling/supportive session.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="2" upper_limit="16"/>
                    <measurement group_id="O2" value="7" lower_limit="4" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O2" value="6.5" lower_limit="4.2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Anxiety and Depression Scale (HADS) HADS-D (Depression)</title>
        <description>The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0–3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0–21). The higher the score, the more likely the patient is showing signs of depression and as a result may benefit from a counseling/supportive session.</description>
        <time_frame>Baseline to Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Thalidomide</title>
            <description>100 mg capsules orally, once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Placebo</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Anxiety and Depression Scale (HADS) HADS-D (Depression)</title>
          <description>The HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0–3). It is designed to measure anxiety and depression (7 items for each subscale). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0–21). The higher the score, the more likely the patient is showing signs of depression and as a result may benefit from a counseling/supportive session.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O2" value="8" lower_limit="3" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="O2" value="8.5" lower_limit="3" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O2" value="6.59" lower_limit="4.2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pittsburgh Sleep Quality Index (PSQI)</title>
        <description>PSQI measures the quality and patterns of sleep. It differentiates poor from good sleep by measuring subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. A participant indicates how frequently each item was experienced on a scale from 0 to 3. The 7 component scores are then summed to obtain a global sleep score that can range from 0 to 21. A score of &gt;/= 5 indicates poor sleepers.</description>
        <time_frame>Baseline to Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Thalidomide</title>
            <description>100 mg capsules orally, once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Placebo</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pittsburgh Sleep Quality Index (PSQI)</title>
          <description>PSQI measures the quality and patterns of sleep. It differentiates poor from good sleep by measuring subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. A participant indicates how frequently each item was experienced on a scale from 0 to 3. The 7 component scores are then summed to obtain a global sleep score that can range from 0 to 21. A score of &gt;/= 5 indicates poor sleepers.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="7.5" upper_limit="14.7"/>
                    <measurement group_id="O2" value="11" lower_limit="5.2" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="5.25" upper_limit="12.7"/>
                    <measurement group_id="O2" value="8.5" lower_limit="3.25" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Symptoms as Measured by Edmonton Symptom Assessment Scale (ESAS)</title>
        <description>ESAS assessment of appetite (symptom) where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity. Evaluated at baseline [± 3 days], 2 weeks[± 3 days] and 4 weeks [± 3 days]</description>
        <time_frame>Baseline to Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide (Baseline)</title>
            <description>Thalidomide 100 mg capsules orally, once a day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Thalidomide (Day 15)</title>
            <description>Thalidomide 100 mg capsules orally, once a day for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Thalidomide (Day 29)</title>
            <description>Thalidomide 100 mg capsules orally, once a day for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Baseline)</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>Placebo (Day 15)</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo (Day 29)</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Symptoms as Measured by Edmonton Symptom Assessment Scale (ESAS)</title>
          <description>ESAS assessment of appetite (symptom) where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity. Evaluated at baseline [± 3 days], 2 weeks[± 3 days] and 4 weeks [± 3 days]</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O3" value="4" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O4" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O5" value="6.5" lower_limit="0" upper_limit="6.5"/>
                    <measurement group_id="O6" value="2.5" lower_limit="2.5" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O2" value="5.5" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O4" value="6.5" lower_limit="4.25" upper_limit="8"/>
                    <measurement group_id="O5" value="5" lower_limit="2.5" upper_limit="5.5"/>
                    <measurement group_id="O6" value="5" lower_limit="3.25" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="4.5" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O3" value="7" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O4" value="6.5" lower_limit="0" upper_limit="6.5"/>
                    <measurement group_id="O5" value="3" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O6" value="5.5" lower_limit="2.25" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O4" value="2.5" lower_limit="0" upper_limit="4.7"/>
                    <measurement group_id="O5" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O6" value="2" lower_limit="0" upper_limit="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Composition as Measured by Body Mass Index (BMI)</title>
        <description>BMI, commonly used to measure overweight and obesity, is a measure of body fat based on a person's weight and height.</description>
        <time_frame>Baseline to Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide (Baseline)</title>
            <description>Thalidomide 100 mg capsules orally, once a day for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Thalidomide (Day 15)</title>
            <description>Thalidomide 100 mg capsules orally, once a day for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Thalidomide (Day 29)</title>
            <description>Thalidomide 100 mg capsules orally, once a day for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Baseline)</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
          <group group_id="O5">
            <title>Placebo (Day 15)</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo (Day 29)</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Composition as Measured by Body Mass Index (BMI)</title>
          <description>BMI, commonly used to measure overweight and obesity, is a measure of body fat based on a person's weight and height.</description>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="20.2" upper_limit="25.4"/>
                    <measurement group_id="O2" value="21.2" lower_limit="20.75" upper_limit="23.8"/>
                    <measurement group_id="O3" value="23.4" lower_limit="19.6" upper_limit="28.2"/>
                    <measurement group_id="O4" value="22.3" lower_limit="19.4" upper_limit="26.9"/>
                    <measurement group_id="O5" value="23.7" lower_limit="19.4" upper_limit="26.9"/>
                    <measurement group_id="O6" value="22.1" lower_limit="19.1" upper_limit="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Cytokines and Receptors</title>
        <description>Cytokines Levels of IL-1β and its receptor IL RA, IL-6 its receptor IL-6R, and TNF-α and its receptors (i.e. tumor necrosis factor receptor (TNFR)) of TNFR1, TNFR2, IL-10, IL-8(serum) measured at baseline, Days 15 and 29. Multiplex bead Immunoassay used to measure serum/plasma levels of IL-1, IL-6, TNF-α, IL-10, IL-8 and their receptors where assay sensitivity for the cytokines was 3-6 pg/mL. Serum IL-10, IL-1β, IL-1RA, IL-6R, sTNF-RI, sTNF-R2 were also analyzed using an enzyme-linked immunosorbent assay device. Lowering cytokine levels can decrease fatigue, increase appetite and decrease anxiety and depression.</description>
        <time_frame>Baseline to Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide (Baseline)</title>
            <description>Thalidomide 100 mg capsules orally, once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Thalidomide (Day 15)</title>
            <description>Thalidomide 100 mg capsules orally, once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Baseline)</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Day 15)</title>
            <description>Two placebo capsules orally, once a day for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Cytokines and Receptors</title>
          <description>Cytokines Levels of IL-1β and its receptor IL RA, IL-6 its receptor IL-6R, and TNF-α and its receptors (i.e. tumor necrosis factor receptor (TNFR)) of TNFR1, TNFR2, IL-10, IL-8(serum) measured at baseline, Days 15 and 29. Multiplex bead Immunoassay used to measure serum/plasma levels of IL-1, IL-6, TNF-α, IL-10, IL-8 and their receptors where assay sensitivity for the cytokines was 3-6 pg/mL. Serum IL-10, IL-1β, IL-1RA, IL-6R, sTNF-RI, sTNF-R2 were also analyzed using an enzyme-linked immunosorbent assay device. Lowering cytokine levels can decrease fatigue, increase appetite and decrease anxiety and depression.</description>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" lower_limit="16.8" upper_limit="280.3"/>
                    <measurement group_id="O2" value="85" lower_limit="18" upper_limit="140"/>
                    <measurement group_id="O3" value="76.4" lower_limit="19.1" upper_limit="133"/>
                    <measurement group_id="O4" value="-6.51" lower_limit="-37.9" upper_limit="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.32" upper_limit="0.74"/>
                    <measurement group_id="O2" value="0.67" lower_limit="0.29" upper_limit="2.77"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.22" upper_limit="1.4"/>
                    <measurement group_id="O4" value="0.57" lower_limit="0.43" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL1RA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="677" lower_limit="501" upper_limit="784"/>
                    <measurement group_id="O2" value="290.7" lower_limit="-901" upper_limit="515"/>
                    <measurement group_id="O3" value="579" lower_limit="266" upper_limit="755"/>
                    <measurement group_id="O4" value="102.3" lower_limit="-639.6" upper_limit="356.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor necrosis factor -a (TNF-a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="13.8" upper_limit="123.1"/>
                    <measurement group_id="O2" value="6.4" lower_limit="-24.8" upper_limit="108.8"/>
                    <measurement group_id="O3" value="21.2" lower_limit="17.8" upper_limit="37.1"/>
                    <measurement group_id="O4" value="6.24" lower_limit="-12.8" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.75" upper_limit="39.7"/>
                    <measurement group_id="O2" value="9.2" lower_limit="3.1" upper_limit="17"/>
                    <measurement group_id="O3" value="12.07" lower_limit="4.3" upper_limit="122.6"/>
                    <measurement group_id="O4" value="11" lower_limit="3.4" upper_limit="316.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" lower_limit="29.7" upper_limit="68.1"/>
                    <measurement group_id="O2" value="2.12" lower_limit="-7.5" upper_limit="11.2"/>
                    <measurement group_id="O3" value="139.9" lower_limit="54.1" upper_limit="289.1"/>
                    <measurement group_id="O4" value="-3.7" lower_limit="-20.9" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6264" lower_limit="4321" upper_limit="30159"/>
                    <measurement group_id="O2" value="5446" lower_limit="3530" upper_limit="16596"/>
                    <measurement group_id="O3" value="13567.4" lower_limit="7186" upper_limit="17164.4"/>
                    <measurement group_id="O4" value="10059.7" lower_limit="5117" upper_limit="19944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor necrosis factor receptor 1 (TNFR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2007.2" lower_limit="418.6" upper_limit="2593.2"/>
                    <measurement group_id="O2" value="-77.2" lower_limit="-161.7" upper_limit="604.6"/>
                    <measurement group_id="O3" value="6788" lower_limit="793.1" upper_limit="34000.9"/>
                    <measurement group_id="O4" value="99.4" lower_limit="-356.4" upper_limit="539.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor necrosis factor receptor 2 (TNFR2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8788" lower_limit="3286" upper_limit="21126"/>
                    <measurement group_id="O2" value="75.4" lower_limit="-693" upper_limit="4319"/>
                    <measurement group_id="O3" value="6788.2" lower_limit="5440" upper_limit="14446"/>
                    <measurement group_id="O4" value="-107.8" lower_limit="-1726" upper_limit="1766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" lower_limit="1.66" upper_limit="7.77"/>
                    <measurement group_id="O2" value="2.58" lower_limit="1.6" upper_limit="7.7"/>
                    <measurement group_id="O3" value="2.83" lower_limit="1.31" upper_limit="4.93"/>
                    <measurement group_id="O4" value="2.6" lower_limit="1.4" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Thalidomide</title>
          <description>100 mg capsules orally, once a day for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Placebo</title>
          <description>Two placebo capsules orally, once a day for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited accrual and attrition led to small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Eduardo Bruera, Professor</name_or_title>
      <organization>University of Texas M.D. Anderson Cancer Center</organization>
      <phone>713-563-4157</phone>
      <email>ammarin@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

